



## CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

December 21, 2004

Date

Shelley P.M. Fussey

**PATENT** 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING

**ANTIBODIES TO** 

**AMINOPHOSPHOLIPIDS** 

Group Art Unit: 1617

Examiner: Sharareh, S.

Atty. Dkt. No.: 4001.002282

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A non-final Official Action on the merits has been received in the present application.

However, this Supplemental Information Disclosure Statement is being filed prior to the mailing

of a final Official Action, notice of allowance or an Action that closes prosecution, and is timely

filed in accordance with 37 C.F.R. § 1.97(c) without a fee in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed

in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent

office in a foreign counterpart to the present application. The listed documents were provided by

European legal representatives of another party in connection with their defense to an Opposition

filed against their European patent by the licensee of the present application.

documents were provided by the other party with a letter dated September 21, 2004, which was

sent to European legal representatives of the licensee of the present application on September 23,

2004. The present statement is being filed within three months of the date of the original letter

and is thus timely.

No fees are due in connection with the filing of this Supplemental Information Disclosure

Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for

any reason, the Examiner should contact the undersigned representative to discuss deduction

from Williams, Morgan & Amerson Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,

Williams, Morgan & Amerson, P.C.

Customer No. 23720

Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458

Agent for Applicants

10333 Richmond, Suite 1100 Houston, Texas, 77042 (713) 934-4079

Date: December 21, 2004

2

			/o'	LE J						
				a Trit &					Page 1 of 1	
	Form P	9 (modified)		Atty. Docket No. 4001.002282		Serial No. 09/351,862				
CANE	. V. /		d Publication for		Applican Thorpe a					
DEC 2.		(Use s	everal sheets if necessar	, l	Filing Da July 12,		Gı 16	roup: 17	·-	
C THA	U.S. Patent Documents See Page			Foreign Patent Documents See Page			Other Art See Page 1			
•				U.S. Paten	t Doc	uments				
	Exam. Init.	Ref. Des.	Document Number	Date	Name		Class	Sub Class	Filing Date of App.	
	Foreign Patent Documents									
	Exam. Init.	Ref. Des.	Document Number	Date	<u>,                                      </u>	Country	Class	Sub Class	Translation Yes/No	
	İ						ł			

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation				
	C120	Bicknell and Harris, "Anticancer Strategies Involving the Vasculature: Vascular Targeting and the Inhibition of Angiogenesis," <i>Seminars in Cancer Biology</i> , 3:399-407, 1992.				
	C121	Bicknell and Harris, "Novel Growth Regulatory Factors and Tumour Angiogenesis," Eur. J. Cancer, 27(6):781-785, 1991.				

**EXAMINER:** 

**DATE CONSIDERED:** 

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.